UPDATE : Saturday, February 22, 2020
Celltrion Healthcare posts ₩713.5 billion in 2018 sales by Lee Han-soo 2019-02-22 17:29
Alteogen applies for P1 trial for Eylea biosimilar by Lee Han-soo 2019-02-22 16:03
Samsung Bioepis, C-Bridge Capital to develop biosimilars in China by Lee Han-soo 2019-02-11 11:23
Samsung BioLogics posts ₩535.8 billion in 2018 sales by Lee Han-soo 2019-02-01 11:56
Celltrion to export biosimilars to Latin America by Lee Han-soo 2019-01-31 11:12
Samsung Bioepis’ biosimilar sales in EU exceed $500 million by Lee Han-soo 2019-01-30 18:17
KIST finds boiling histotripsy’s mechanism to remove tumor tissue by Cho In-sung 2019-01-24 11:30
FDA OKs Samsung Bioepis’ first oncology medicine by Lee Han-soo 2019-01-21 11:43
Celltrion wins patent dispute on Truxima by Lee Han-soo 2019-01-18 11:47
Over 1,000 bio-ventures set up in past 3 years by Lee Han-soo 2019-01-17 22:05
CL Bio wins patent for substance that improves antidiabetic functions by Lee Han-soo 2019-01-14 12:34
Medipost, LG Chem to develop stem cell therapy by Lee Han-soo 2019-01-08 17:55
Samsung Bioepis to expand business in China by Lee Han-soo 2019-01-07 12:30
Celltrion’s Truxima claims 35% of European rituximab market by Lee Han-soo 2019-01-04 15:54
Alteogen wins patent on optimizing incubation conditions for Eylea biosimilar by Lee Han-soo 2019-01-03 16:01
Newly listed pharmaceuticals suffer market cap declines by Nam Doo-hyun 2018-12-21 15:13
Celltrion Healthcare’s sell-off of domestic sales right raises window-dressing controversy by Nam Doo-hyun 2018-12-17 12:48
Samsung BioLogics’ market cap rises after accounting issue by Nam Doo-hyun 2018-12-13 15:33
‘Bispecific antibody market offers promising outlook’ by Nam Doo-hyun 2018-12-12 16:27
Samsung BioLogics, Celltrion shares soar despite uncertainty by Lee Han-soo 2018-12-12 16:27
Back to Top